## **Core Concept**
Intravesical therapy for superficial bladder cancer involves the direct instillation of therapeutic agents into the bladder to treat or prevent cancer recurrence. This approach is used to minimize systemic side effects and maximize local drug concentrations. The goal is to eliminate or control tumor growth within the bladder.

## **Why the Correct Answer is Right**
The correct answer, **Bacillus Calmette-Guérin (BCG)**, is considered the most effective intravesical therapy for superficial bladder cancer, particularly for carcinoma in situ (CIS) and high-risk non-muscle invasive bladder cancer. BCG works by stimulating an immune response against cancer cells. It is a live, attenuated vaccine that induces a local immune reaction, leading to the destruction of cancer cells. Studies have shown that BCG significantly reduces the risk of recurrence and progression of superficial bladder cancer.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Mitomycin C is a chemotherapeutic agent used in intravesical therapy for superficial bladder cancer. While it is effective, especially for low-risk disease, its efficacy is generally considered lower than that of BCG for high-risk disease or carcinoma in situ.
- **Option C:** Interferon is another agent used in intravesical therapy, often in combination with BCG for BCG-refractory or relapsed disease. It has immunomodulatory effects but is not as effective as BCG for initial treatment of high-risk superficial bladder cancer.
- **Option D:** Epirubicin is a chemotherapeutic agent that can be used for intravesical therapy. Like mitomycin C, it has a role in treating superficial bladder cancer but is generally considered less effective than BCG for preventing recurrence and progression, especially in high-risk cases.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **BCG is the standard intravesical therapy for high-risk non-muscle invasive bladder cancer and carcinoma in situ**, significantly reducing recurrence and progression. However, BCG can cause significant side effects, and its use requires careful patient selection and monitoring.

## **Correct Answer:** B. Bacillus Calmette-Guérin (BCG).